Treatment helps people with type 2 diabetes achieve blood sugar level targets
People with type 2 diabetes involved in the study reported significantly greater satisfaction in favour of once-weekly insulin icodec compared with insulin degludec at 26 weeks according to results of a survey carried out by researchers.
Martin Holst Lange, Executive Vice President Development, Novo Nordisk, said: “We are very pleased to see the promising results from the ONWARDS programme so far. The patient-reported outcomes data we see in ONWARDS 2 further strengthen our belief that insulin icodec has the potential to become the ideal insulin for people living with type 2 diabetes initiating insulin treatment.”
The average weekly insulin dose was 268 U/week for insulin icodec vs 244 U/week for insulin degludec. The estimated mean change in body weight from baseline to week 26 was 1.40kg for for insulin icodec compared with –0.30 kg for insulin degludec.
A decrease in body weight of 1.40kg was also reported in people taking insulin icodec compared with a loss of 0.30kg for those taking insulin degludec.
Researchers concluded: “In the trial, once-weekly insulin icodec appeared to have a safe and well-tolerated profile. There was less than one hypoglycaemic episode per patient-year for insulin icodec and insulin degludec (0.73 events and 0.27 events per patient-year, respectively, with no statistically significant difference). As previously reported, no severe hypoglycaemia events were observed for people treated with insulin icodec.”
Find out more about type 2 diabetes
Support DRWF by making a donation here
Find out more about DRWF-funded research here
Find out more about DRWF fundraising here
To receive the charity’s latest bulletins as they become available, please sign up here
Read DRWF diabetes information leaflets here
Join the Diabetes Wellness Network here
I would like to make a regular donation of
I would like to make a single donation of